Lin BioScience, Inc. (TPEX:6696)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
133.50
-0.50 (-0.37%)
Apr 2, 2025, 1:52 PM CST
Market Cap 10.50B
Revenue (ttm) n/a
Net Income (ttm) -731.66M
Shares Out 78.67M
EPS (ttm) -9.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 94,681
Average Volume 290,911
Open 133.50
Previous Close 134.00
Day's Range 132.00 - 134.00
52-Week Range 70.00 - 180.50
Beta 0.05
RSI 29.87
Earnings Date Apr 23, 2025

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Zhengqi Wang
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6696
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.